InteRNA Technologies

ProQR Therapeutics N.V.PRQR · BiotechLeiden, Netherlands

68% matchPublic

ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.

Atalanta TherapeuticsBiotechnologyUnited States

68% match

Atalanta Therapeutics is a biotechnology company headquartered in Boston, Massachusetts, focused on developing RNA-interference therapeutic interventions for neurodegenerative diseases. The company launched with significant venture backing from life sciences investors.

miRecule, Inc.BiotechnologyUnited States

68% matchPrivate

miRecule, Inc. is a biotechnology company headquartered in Gaithersburg, Maryland, focused on developing RNA therapeutics.

ARTHEx BiotechBiotechnologySpain

67% match

ARTHEx Biotech S.L. is a spin-off company of the University of Valencia dedicated to developing advanced RNA-based treatments against genetic diseases. The company maintains its headquarters in Paterna and Valencia, Spain.

Phlox TherapeuticsBiotechnologyNetherlands

67% match

Phlox Therapeutics is a private biotechnology company pioneering RNA-based gene therapies to alleviate and cure severe genetic heart diseases and cardiomyopathies. Headquartered in Naarden, Netherlands, the company focuses on innovative cardiovascular treatments.

Aptadir TherapeuticsBiotechnologyItaly

67% match

Aptadir Therapeutics is a biotechnology company based in Milan, Italy, specializing in the development of RNA inhibitor-based therapeutics. The firm focuses on creating novel treatments for intractable cancers and genetic disorders.